Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E. Neal, J. Athene Lane, Michael Davis et al.|European Urology|2019Cited by 150
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, Duncan C. Gilbert et al.|The Lancet|2021Cited by 49